679 related articles for article (PubMed ID: 32512290)
21. Host Cell and SARS-CoV-2-Associated Molecular Structures and Factors as Potential Therapeutic Targets.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Roshan R; Azam F; Mehta J; Handu S; Prasad R; Jain N; Pandey AK; Dhamija P
Cells; 2021 Sep; 10(9):. PubMed ID: 34572076
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor.
Mjaess G; Karam A; Aoun F; Albisinni S; Roumeguère T
Prog Urol; 2020 Sep; 30(10):484-487. PubMed ID: 32620366
[TBL] [Abstract][Full Text] [Related]
23. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.
Divani AA; Andalib S; Di Napoli M; Lattanzi S; Hussain MS; Biller J; McCullough LD; Azarpazhooh MR; Seletska A; Mayer SA; Torbey M
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104941. PubMed ID: 32689643
[TBL] [Abstract][Full Text] [Related]
24. Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection.
Robinson FA; Mihealsick RP; Wagener BM; Hanna P; Poston MD; Efimov IR; Shivkumar K; Hoover DB
Am J Physiol Heart Circ Physiol; 2020 Nov; 319(5):H1059-H1068. PubMed ID: 33036546
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
[TBL] [Abstract][Full Text] [Related]
26. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
Mondal T; Shivange G; Habieb A; Tushir-Singh J
Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
[TBL] [Abstract][Full Text] [Related]
27. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
28. Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor
Nowak JK; Lindstrøm JC; Kalla R; Ricanek P; Halfvarson J; Satsangi J
Gastroenterology; 2020 Sep; 159(3):1151-1154.e2. PubMed ID: 32413354
[No Abstract] [Full Text] [Related]
29. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
30. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
31. The Science Underlying COVID-19: Implications for the Cardiovascular System.
Liu PP; Blet A; Smyth D; Li H
Circulation; 2020 Jul; 142(1):68-78. PubMed ID: 32293910
[TBL] [Abstract][Full Text] [Related]
32. ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities.
Zamorano Cuervo N; Grandvaux N
Elife; 2020 Nov; 9():. PubMed ID: 33164751
[TBL] [Abstract][Full Text] [Related]
33. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
Guo X; Chen Z; Xia Y; Lin W; Li H
J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
[TBL] [Abstract][Full Text] [Related]
34. Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection.
Klaassen K; Stankovic B; Zukic B; Kotur N; Gasic V; Pavlovic S; Stojiljkovic M
Infect Genet Evol; 2020 Oct; 84():104498. PubMed ID: 32771700
[TBL] [Abstract][Full Text] [Related]
35. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein.
Pillay TS
J Clin Pathol; 2020 Jul; 73(7):366-369. PubMed ID: 32376714
[TBL] [Abstract][Full Text] [Related]
36. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide bioinformatics analysis of human protease capacity for proteolytic cleavage of the SARS-CoV-2 spike glycoprotein.
Matveev EV; Ponomarev GV; Kazanov MD
Microbiol Spectr; 2024 Feb; 12(2):e0353023. PubMed ID: 38189333
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects.
Wrobel AG; Benton DJ; Xu P; Roustan C; Martin SR; Rosenthal PB; Skehel JJ; Gamblin SJ
Nat Struct Mol Biol; 2020 Aug; 27(8):763-767. PubMed ID: 32647346
[TBL] [Abstract][Full Text] [Related]
39. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Nicolau LAD; Magalhães PJC; Vale ML
Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
[TBL] [Abstract][Full Text] [Related]
40. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?
Perrotta F; Matera MG; Cazzola M; Bianco A
Respir Med; 2020 Jul; 168():105996. PubMed ID: 32364961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
